<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA Psychiatry: Metabolic Diseases Topic Collection</title>
    <link>http://archpsyc.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Mon, 31 Dec 2012 00:00:00 GMT</pubDate>
    <lastBuildDate>Tue, 01 Jan 2013 00:48:54 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@archpsyc.jamanetwork.com</managingEditor>
    <webMaster>webmaster@archpsyc.jamanetwork.com</webMaster>
    <item>
      <title>Prevention of Relapse Following Cognitive Therapy vs Medications in Moderate to Severe Depression</title>
      <link>http://archpsyc.jamanetwork.com/article.aspx?articleID=208447</link>
      <pubDate>Fri, 01 Apr 2005 00:00:00 GMT</pubDate>
      <author>Hollon SD, DeRubeis RJ, Shelton RC, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Background&lt;/div&gt;Antidepressant medication prevents the return of depressive symptoms, but only as long as treatment is continued.&lt;div class="boxTitle"&gt;Objectives&lt;/div&gt;To determine whether cognitive therapy (CT) has an enduring effect and to compare this effect against the effect produced by continued antidepressant medication.&lt;div class="boxTitle"&gt;Design&lt;/div&gt;Patients who responded to CT in a randomized controlled trial were withdrawn from treatment and compared during a 12-month period with medication responders who had been randomly assigned to either continuation medication or placebo withdrawal. Patients who survived the continuation phase without relapse were withdrawn from all treatment and observed across a subsequent 12-month naturalistic follow-up.&lt;div class="boxTitle"&gt;Setting&lt;/div&gt;Outpatient clinics at the University of Pennsylvania and Vanderbilt University.&lt;div class="boxTitle"&gt;Patients&lt;/div&gt;A total of 104 patients responded to treatment (57.8% of those initially assigned) and were enrolled in the subsequent continuation phase; patients were initially selected to represent those with moderate to severe depression.&lt;div class="boxTitle"&gt;Interventions&lt;/div&gt;Patients withdrawn from CT were allowed no more than 3 booster sessions during continuation; patients assigned to continuation medication were kept at full dosage levels.&lt;div class="boxTitle"&gt;Main Outcome Measures&lt;/div&gt;Relapse was defined as a return, for at least 2 weeks, of symptoms sufficient to meet the criteria for major depression or Hamilton Depression Rating Scale scores of 14 or higher during the continuation phase. Recurrence was defined in a comparable fashion during the subsequent naturalistic follow-up.&lt;div class="boxTitle"&gt;Results&lt;/div&gt;Patients withdrawn from CT were significantly less likely to relapse during continuation than patients withdrawn from medications (30.8% vs 76.2%; &lt;span style="font-style:italic;"&gt;P&lt;/span&gt; = .004), and no more likely to relapse than patients who kept taking continuation medication (30.8% vs 47.2%; &lt;span style="font-style:italic;"&gt;P&lt;/span&gt; = .20). There were also indications that the effect of CT extends to the prevention of recurrence.&lt;div class="boxTitle"&gt;Conclusions&lt;/div&gt;Cognitive therapy has an enduring effect that extends beyond the end of treatment. It seems to be as effective as keeping patients on medication.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">62</prism:volume>
      <prism:number xmlns:prism="prism">4</prism:number>
      <prism:startingPage xmlns:prism="prism">417</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">422</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/archpsyc.62.4.417</prism:doi>
      <guid>http://archpsyc.jamanetwork.com/article.aspx?articleID=208447</guid>
    </item>
  </channel>
</rss>